Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    OK!

    Registrations are still open for the Virtual Dialogue:: Saturday, April 30 1:00PM – 2:30PM (EST / New York Time)

    March 19th, 2022Join Us: Registration is Still Open The Chondrosarcoma Foundation, Inc. will host their fourth International Forum / Virtual Dialogue featuring the following prominent experts to address new innovations, findings and technologies to improve the...

    Read Article

    Clinical Pathology Unknowns

    March 18th, 2022 The Johns Hopkins Department of Pathology is proud to announce the launch of a new web site, "Clinical Pathology Unknowns" (https://apps.pathology.jhu.edu/cp/), an interactive clinical pathology educational resource. This...

    Read Article

    Register for our Virtual Dialogue scheduled for April 30 at 1:00pm via Zoom

    March 6th, 2022The Chondrosarcoma Foundation, Inc. will host their fourth International Forum / Virtual Dialogue: Moving Forward in Diagnosing and Treating Chondrosarcoma. In the spirit of sharing and passing knowledge about Chondrosarcoma, we invite you to...

    Read Article

    Chondrosarcoma Foundation will host the Fourth Virtual Dialogue on Saturday, April 30 at 1:00PM EST / New York time VIA Zoom

    February 23rd, 2022The Chondrosarcoma Foundation, Inc. will host their fourth International Forum / Virtual Dialogue featuring the following prominent experts to address new innovations, findings and technologies to improve the treatment of Chondrosarcoma. Anthony P....

    Read Article

    Phase 2 Study of Dasatinib (Sprycel) in Patients With Alveolar Soft,Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid,Sarcoma, or Solitary Fibrous Tumor

    February 20th, 2022About 20% of people with chondrosarcoma responded to the drug (tumor shrinkage by 20%). On average people with CS were on the drug for about 4-5 months before it was deemed ineffective though. In looking at the criteria for CS patients on the...

    Read Article

    CTOS & SPAEN Roundtable Paper “Global Patient Involvement in Sarcoma Care” published

    February 14th, 2022 CTOS & SPAEN Roundtable Paper “Global Patient Involvement in Sarcoma Care“ Dear SPAEN Members AND FRIENDS! We are happy and proud to announce that CTOS & SPAEN Roundtable Paper “Global Patient Involvement in Sarcoma...

    Read Article

    A list of clinical trials available for CS patients:

    February 11th, 2022A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma https://www.clinicaltrials.gov/ct2/show/NCT05193188?cond=Chondrosarcoma&draw=2&rank=1 Study of INBRX-109 in Conventional...

    Read Article

    Celebrating Chondrosarcoma Awareness Day

    February 6th, 2022To honor Chondrosarcoma Awareness Day. our family and friends put on our Yellow ribbons wore yellow clothes we went to my daughter Shayna's grave site this afternoon. My brother Rick drove up from Atlanta, Georgi, my brother Mark, his wife Karen and...

    Read Article